{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:53:46Z","timestamp":1781488426725,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16015-0","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:59:22Z","timestamp":1777417162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting response to neoadjuvant hormonal therapy and prognostic outcomes in high-risk prostate cancer using MRI-based radiomics"],"prefix":"10.1186","volume":"26","author":[{"given":"Hai","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Xin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian- Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"16015_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"16015_CR2","doi-asserted-by":"publisher","first-page":"30823","DOI":"10.1038\/nrclinonc.2014.68","volume":"11","author":"AJ Chang","year":"2014","unstructured":"Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11:30823.","journal-title":"Nat Rev Clin Oncol"},{"key":"16015_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.urolonc.2019.07.009","volume":"37","author":"J Pan","year":"2019","unstructured":"Pan J, Chi C, Qian H, Zhu Y, Shao X, Sha J, et al. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: a retrospective comparative study. Urol Oncol. 2019;37:991\u20138.","journal-title":"Urol Oncol"},{"issue":"12","key":"16015_CR4","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41585-021-00514-9","volume":"18","author":"G Devos","year":"2021","unstructured":"Devos G, Devlies W, De Meerleer G, et al. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. Nat Rev Urol. 2021;18(12):739\u201362.","journal-title":"Nat Rev Urol"},{"key":"16015_CR5","doi-asserted-by":"publisher","unstructured":"Mottet N,van den Bergh RCN, Briers E, et al. Re: EAU guidelines: prostate cancer 2019. Eur Urol. 2019;76(6):871. https:\/\/doi.org\/10.1016\/j.eururo.2019.07.014.","DOI":"10.1016\/j.eururo.2019.07.014"},{"key":"16015_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","volume":"35","author":"MD Shelley","year":"2009","unstructured":"Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35:9\u201317.","journal-title":"Cancer Treat Rev"},{"key":"16015_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41585-018-0017-x","volume":"15","author":"G Pignot","year":"2018","unstructured":"Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, et al. Systemic treatments for high-risk localized prostate cancer. Nat Rev Urol. 2018;15:498\u2013510.","journal-title":"Nat Rev Urol"},{"issue":"4","key":"16015_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.4103\/aja.aja_96_20","volume":"23","author":"W Liu","year":"2021","unstructured":"Liu W, Yao Y, Liu X, Liu Y, Zhang G-M. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23(4):429\u201336.","journal-title":"Asian J Androl"},{"issue":"4","key":"16015_CR9","first-page":"949","volume":"18","author":"M Dolezel","year":"2013","unstructured":"Dolezel M, Odrazka K, Vanasek J, et al. Neoadjuvant hormonal therapy in prostate cancer\u2014impact of PSA level before radiotherapy. J BUON. 2013;18(4):949\u201353.","journal-title":"J BUON"},{"issue":"4","key":"16015_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","volume":"50","author":"Z-B Ke","year":"2023","unstructured":"Ke Z-B, Chen S-M, Chen J-Y, et al. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET\/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study. Eur J Nucl Med Mol Imaging. 2023;50(4):1240\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"16015_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"16015_CR12","doi-asserted-by":"crossref","unstructured":"Hu T, Gong J, Sun Y, Li M, Cai C, Li X, Cui Y, Zhang X, Tong T. Magnetic resonance imaging-based radiomics analysis for prediction of treatment response to neoadjuvant chemoradiotherapy and clinical outcome in patients with locally advanced rectal cancer: a large multicentric and validated study. MedComm (2020). 2024;5(7):e609.","DOI":"10.1002\/mco2.609"},{"issue":"6","key":"16015_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s11547-018-0966-4","volume":"124","author":"H Abdollahi","year":"2019","unstructured":"Abdollahi H, Mofid B, Shiri I, et al. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer. Radiol Med. 2019;124(6):555\u201367.","journal-title":"Radiol Med"},{"issue":"1","key":"16015_CR14","first-page":"107","volume":"22","author":"CD Petraki","year":"2007","unstructured":"Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol. 2007;22(1):107\u201318.","journal-title":"Histol Histopathol"},{"issue":"1","key":"16015_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-025-13826-5","volume":"25","author":"H Huang","year":"2025","unstructured":"Huang H, Wang T, Li W, Wu Z, Wang X, Xing J, Chen B, Zhang K. Safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer (SEGNO): study protocol for an open-label prospective phase II umbrella clinical trial. BMC Cancer. 2025;25(1):432.","journal-title":"BMC Cancer"},{"issue":"14","key":"16015_CR16","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1002\/cam4.70001","volume":"13","author":"XH Wu","year":"2024","unstructured":"Wu XH, Ruan ZT, Ke ZB, Lin F, Chen JY, Xue YT, Lin B, Chen SH, Chen DN, Zheng QS, Xue XY, Wei Y, Xu N. Magnetic resonance imaging-based radiomics nomogram for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer. Cancer Med. 2024;13(14):e70001.","journal-title":"Cancer Med"},{"issue":"9","key":"16015_CR17","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.jpha.2025.101232","volume":"15","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang J, Li D, Wu R, Huang J, Ye L, Tuo Z, Yu Q, Shao F, Wusiman D, Cho WC, Koh SB, Xiong W, Feng D. Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance. J Pharm Anal. 2025;15(9):101232.","journal-title":"J Pharm Anal"},{"key":"16015_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1756-8722-7-20","volume":"7","author":"M Thalgott","year":"2014","unstructured":"Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol. 2014;7:20.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"16015_CR19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, Chen X, Jiang XS, McCall SJ, Inman BA, Huang J. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022;81(5):446\u201355.","journal-title":"Eur Urol"},{"issue":"11","key":"16015_CR20","first-page":"13","volume":"36","author":"B Miron","year":"2010","unstructured":"Miron B, Kursa WRR. Feature selection with the boruta package. J Statist Softw. 2010;36(11):13.","journal-title":"J Statist Softw"},{"issue":"12","key":"16015_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"16015_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1515\/cclm-2014-0988","volume":"53","author":"X Filella","year":"2015","unstructured":"Filella X, Foj L. Emerging biomarkers in the detection and prognosis of prostate cancer. Clin Chem Lab Med. 2015;53:963\u201373.","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"16015_CR23","first-page":"41","volume":"15","author":"S Huang","year":"2018","unstructured":"Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of support vector machine (SVM) learning in cancer genomics. Cancer Genomics Proteom. 2018;15(1):41\u201351.","journal-title":"Cancer Genomics Proteom"},{"issue":"1","key":"16015_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1148\/radiol.14140770","volume":"275","author":"KE Emblem","year":"2015","unstructured":"Emblem KE, Pinho MC, Zollner FG, et al. A generic support vector machine model for preoperative glioma survival associations. Radiology. 2015;275(1):228\u201334.","journal-title":"Radiology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16015-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:38:15Z","timestamp":1781487495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16015"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16015-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8655062\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Fudan University affiliated Huadong hospital, and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"749"}}